Advertisement
Advertisement
BCYC
Bicycle Therapeutics plc - ADR
3.69
USDSponsored
-0.08
-2.12%
Nov 10, 15:59 UTC -5
Closed
After-Market
3.69
0.00
-0.14%
Bicycle Therapeutics plc - ADR (BCYC) Earnings
BCYC Earnings Reports
Positive Surprise Ratio
BCYC beat 14 of 30 last estimates.
47%
Next Report
Date of Next Report
Mar 15, 2027
Estimate for Q4 26 (Revenue/ EPS)
$1.86M
/-$0.44
Implied change from Q3 26 (Revenue/ EPS)
-94.54%
/+193.33%
Implied change from Q4 25 (Revenue/ EPS)
-96.12%
/+57.14%
Bicycle Therapeutics plc - ADR earnings per share and revenue
On Oct 29, 2026, BCYC reported earnings of -0.15 USD per share (EPS) for Q3 26, beating the estimate of -0.44 USD, resulting in a 66.04% surprise. Revenue reached 34.06 million, compared to an expected 6.19 million, with a 450.13% difference. The market reacted with a -1.55% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.44 USD, with revenue projected to reach 1.86 million USD, implying an increase of 193.33% EPS, and decrease of -94.54% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Bicycle Therapeutics plc - ADR's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Bicycle Therapeutics plc - ADR reported EPS of -$0.15, beating estimates by 66.04%, and revenue of $34.06M, 450.13% above expectations.
How did the market react to Bicycle Therapeutics plc - ADR's Q3 2026 earnings?
The stock price moved down -1.55%, changed from $3.88 before the earnings release to $3.82 the day after.
When is Bicycle Therapeutics plc - ADR expected to report next?
The next earning report is scheduled for Mar 15, 2027.
What are the forecasts for Bicycle Therapeutics plc - ADR's next earnings report?
Based on --
analysts, Bicycle Therapeutics plc - ADR is expected to report EPS of -$0.44 and revenue of $1.86M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.